Enveric Biosciences

Historical price data

Enveric Biosciences is a development-stage biotech focused on creating novel small-molecule therapeutics that promote neuroplasticity for treating mental health disorders, without inducing hallucinations. Its core strategy is powered by The Psybrary™, a proprietary platform used to generate and screen hundreds of novel compounds, leading to a robust IP portfolio. The company's most advanced program, EB-003, is in late preclinical development, targeting a first-in-class, prescription-based model for difficult-to-treat conditions. Enveric's approach aims to overcome key barriers to adoption in the psychedelic-inspired therapeutic space by developing drugs suitable for conventional clinical use.

The Psybrary™ is a proprietary discovery and development platform that systematically generates and screens libraries of novel neuroplastogenic compounds, aiming to dissociate therapeutic neuroplasticity from hallucinogenic psychoactivity.

Enveric competes directly with other non-hallucinogenic neuroplastogen developers (e.g., Gilgamesh, Delix) and indirectly with classic psychedelic therapy companies. Its differentiation lies in its Psybrary™ platform, EB-003's dual receptor mechanism, and a strong focus on a scalable prescription drug model.